Physician

Mark L Mansfield, M.D.

According to 2025 Medicare claims, Mark Mansfield, M.D. (NPI: 1134113251) practices family practice in the Pocatello, ID market, with the plurality of this provider's patient population coming from Bannock, ID. This provider's primary affiliated billing organization is PRIMARY CARE SPECIALISTS, PA (NPI: 1508875881; TIN: 820510113) and primary practice location at 83201-5824. Mansfield is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), and Aledade 151 Northern Territories MSSP Enhanced (ACO ID: A5349), participating under the MSSP model.

Mansfield's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 240 traditional Medicare patients, billed 1,319 HCPCS/CPT codes, and received $74,287 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 1,903 prescription claims across 329 beneficiaries totaling $106,625 in drug costs, led by Ozempic (Semaglutide). DME data shows 51 claims. Open Payments data shows 2 records totaling $31. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,915 and ending at $12,161.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	325	12,865	$131,108
2016	330	4,718	$152,051
2017	363	4,999	$169,626
2018	354	4,891	$164,496
2019	373	4,743	$162,614
2020	322	3,989	$141,735
2021	370	2,527	$123,241
2022	316	2,980	$172,702
2023	293	2,497	$144,791
2024	240	1,319	$74,287

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	237	1,451	$82,489
2016	240	1,559	$76,424
2017	252	1,846	$93,070
2018	264	2,016	$99,981
2019	305	2,270	$149,710
2020	279	2,788	$171,121
2021	336	3,085	$200,385
2022	334	2,035	$111,511
2023	315	1,871	$119,138
2024	329	1,903	$106,625

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	50	101	$800
2016	13	60	$536
2017	N/R	70	$2,175
2018	N/R	80	$3,316
2019	N/R	46	$991
2020	N/R	26	$1,118
2021	N/R	22	$499
2022	N/R	14	$284
2023	N/R	46	$2,283
2024	N/R	51	$9,660

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	167	167	$119
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	84	108	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	161	228	$63
G0444	Annual depression screening, 5 to 15 minutes	150	150	$17
36415	Insertion of needle into vein for collection of blood sample	88	99	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	19	812	$23,533
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	810	$16,418
Levothyroxine Sodium	Levothyroxine Sodium	157	11,796	$1,766
Atorvastatin Calcium	Atorvastatin Calcium	192	16,620	$1,133
Omeprazole	Omeprazole	103	8,350	$855

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	23	$8,678
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	28	$982

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$31	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark L. Mansfield, M.D.?

Tedicare shows public-source Medicare data for Mark L. Mansfield, M.D. (NPI 1134113251), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark L. Mansfield, M.D. have ACO affiliation data?

Mark L. Mansfield, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), and Aledade 151 Northern Territories MSSP Enhanced (MSSP, ACO ID A5349).

What billing organization is linked to Mark L. Mansfield, M.D.?

Mark L. Mansfield, M.D. is linked to PRIMARY CARE SPECIALISTS, PA (billing NPI 1508875881) in the available physician profile data.

Does Mark L. Mansfield, M.D. have Open Payments data?

Mark L. Mansfield, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.